New LaunchJun 18, 2026, 05:22 PM
VERAXA Biotech Validates BiTAC-ADC Platform, Seeks Partners at BIO 2026
AI Summary
VERAXA Biotech AG announced the establishment of in vitro proof-of-concept data for its novel BiTAC-ADC technology platform, designed for more precise and targeted cancer therapies. The technology demonstrated the ability to discriminate between breast cancer and healthy cells and efficiently kill 3D tumor cell spheroids. The company will leverage these findings and its BiTAC-TCE platform to launch partnering discussions at the BIO International Convention from June 22-25, 2026, aiming to address off-tumor toxicity challenges in current ADC technologies.
Key Highlights
- VERAXA Biotech established in vitro proof-of-concept for its novel BiTAC-ADC technology platform.
- BiTAC-ADCs demonstrated discrimination between breast cancer and healthy cells in studies.
- The platform showed efficient, dose-dependent killing of 3D tumor cell spheroids.
- VERAXA will attend the BIO International Convention (June 22-25, 2026) to discuss partnering opportunities.
- The BiTAC-ADC platform aims to improve safety and targeted efficacy of next-generation ADC therapeutics.
- Initial data from the BiTAC-TCE program was recently presented at the AACR Annual Meeting.
- The company now has two viable and clearly differentiated product platform technologies.
Price Impact
More from VRXA